cdk2-in-13

CDK2-IN-13 is a potent Cyclin-dependent kinase 2 (CDK2) inhibitor (IC50 value: 12 µM).CDK2-IN-13 is involved in cell cycle regulation and can arrest the cell cycle. CDK2-IN-13 prevents cell division and proliferation, induces apoptosis, and can be used in cancer research.

WEE1-IN-11 (Compound 13) serves as a potent CDK2 inhibitor with an IC50 of 2.0 nM. It exhibits inhibitory effects on several cell lines, including NCI-H446, A427, OVCAR3, C33A, and WiDr, with respective IC50 values of 93.9, 34.5, 86.7, 23.1, and 85 nM.

CDK2/MDM2-IN-1 (III-13) is a dual inhibitor targeting both CDK2 and MDM2, exhibiting an IC50 value of 2.60 nM against CDK2, and demonstrating antitumor activity.

CDK2 degrader7 is an orally active CDK2 degrader with DC50 values of 13 nM in MKN1 cells and 17 nM in TOV21G cells. It induces G1 phase arrest in MKN1 cells and achieves tumor suppression in the HCC1569 (CCNE1 amplified) xenograft model. CDK2 degrader7 is utilized in research on CCNE1 amplification-type cancers.

ARUK2010694 (Compound 20) is a potent and selective inhibitor of NUAK1, with a pIC50 value of 8.7. It also inhibits the activity of CDK2, CDK4, and CDK6, with inhibition rates of 13%, 63%, and 32% respectively at a concentration of 1 μM. ARUK2010694 is applicable in research on neurological disorders, including Alzheimer's disease (AD).